Precision radiation tested to fight back against relapsed blood cancer
NCT ID NCT01794572
Summary
This early-phase study tested a new, more targeted form of radiation to the bone marrow, combined with high-dose chemotherapy, for patients whose multiple myeloma had returned once. The goal was to see if this intense treatment, followed by a patient's own stem cells, was safe and to find the best radiation dose. The trial was small and terminated early, focusing on safety and determining the maximum dose patients could tolerate.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CHU Claude Huriez, service d'hématologie
Lille, 59037, France
-
CHU Haut-Leveque, service d'Hématologie
Bordeaux, 33604, France
-
CHU Hautepierre, service d'hématologie
Strasbourg, 67098, France
-
CHU Hotel-Dieu, service d'hématologie
Nantes, 44093, France
-
CLCC Bergonie, service de radiotherapie
Bordeaux, 33076, France
-
CLCC ICO, service de radiothérapie
Saint-Herblain, 44805, France
-
CLCC Oscar Lambret, service de radiothérapie
Lille, 59020, France
-
CLCC Paul Strauss, service de radiothérapie
Strasbourg, 67091, France
Conditions
Explore the condition pages connected to this study.